• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Hydroquinolones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolones and derivatives Hydroquinolones

Introduction to 7-(Trifluoromethyl)quinolin-2-OL (CAS No. 1011533-24-6)

7-(Trifluoromethyl)quinolin-2-OL, identified by its Chemical Abstracts Service number CAS No. 1011533-24-6, is a significant compound in the realm of pharmaceutical chemistry and bioorganic synthesis. This heterocyclic aromatic alcohol features a trifluoromethyl group at the 7-position of the quinoline scaffold, which imparts unique electronic and steric properties essential for its applications in medicinal chemistry.

The structural motif of 7-(Trifluoromethyl)quinolin-2-OL combines the versatility of the quinoline core with the electron-withdrawing nature of the trifluoromethyl substituent. This combination enhances the compound's potential as a building block for the development of novel therapeutic agents. The presence of a hydroxyl group at the 2-position further expands its synthetic utility, allowing for diverse functionalization strategies.

In recent years, there has been a growing interest in quinoline derivatives due to their broad spectrum of biological activities. The trifluoromethyl group, in particular, is renowned for its ability to modulate pharmacokinetic properties, such as metabolic stability and lipophilicity, making it a preferred moiety in drug design. 7-(Trifluoromethyl)quinolin-2-OL exemplifies this trend, as it serves as a precursor for synthesizing more complex molecules with enhanced pharmacological profiles.

One of the most compelling aspects of 7-(Trifluoromethyl)quinolin-2-OL is its role in the development of antimicrobial and anticancer agents. Quinoline derivatives have a long history of use in treating parasitic infections, and modifications to their structure have led to the discovery of drugs like chloroquine and mefloquine. The introduction of a trifluoromethyl group has further refined these properties, leading to compounds with improved efficacy and reduced side effects.

Recent studies have highlighted the potential of 7-(Trifluoromethyl)quinolin-2-OL in targeting specific enzymatic pathways involved in cancer progression. For instance, research has demonstrated that quinoline-based compounds can inhibit tyrosine kinases, which are crucial for signal transduction in cancer cells. The trifluoromethyl group enhances binding affinity by increasing lipophilicity and reducing metabolic degradation, thereby improving therapeutic outcomes.

The hydroxyl group at the 2-position of 7-(Trifluoromethyl)quinolin-2-OL provides an additional handle for chemical modification. This functionality can be exploited to introduce various pharmacophores or to link the compound to other biomolecules through conjugation techniques. Such modifications have been instrumental in developing prodrugs and targeted drug delivery systems, further expanding the therapeutic applications of this compound.

In addition to its pharmaceutical applications, 7-(Trifluoromethyl)quinolin-2-OL has shown promise in materials science. The unique electronic properties of quinoline derivatives make them suitable candidates for organic semiconductors and light-emitting diodes (LEDs). The presence of the trifluoromethyl group can influence charge transport properties, making these compounds valuable for developing next-generation electronic devices.

The synthesis of 7-(Trifluoromethyl)quinolin-2-OL typically involves multi-step organic reactions, including Friedel-Crafts alkylation followed by reduction and functional group transformations. Advances in synthetic methodologies have enabled more efficient and scalable production processes, ensuring that researchers have access to sufficient quantities for both academic and industrial applications.

The growing body of literature on quinoline derivatives underscores their importance in modern drug discovery. As our understanding of biological pathways continues to expand, so does the demand for structurally diverse compounds like 7-(Trifluoromethyl)quinolin-2-OL. Its unique combination of electronic and steric properties makes it an indispensable tool for medicinal chemists seeking to develop innovative therapies.

In conclusion, 7-(Trifluoromethyl)quinolin-2-OL (CAS No. 1011533-24-6) is a versatile compound with significant implications in pharmaceutical chemistry and beyond. Its structural features and synthetic accessibility make it a valuable intermediate for developing antimicrobial, anticancer, and materials science applications. As research progresses, this compound will undoubtedly continue to play a pivotal role in advancing therapeutic innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)